Benchmark Reiterates Speculative Buy Rating on Reviva Pharmaceuticals (RVPH)

May 23, 2025 7:48 AM EDT Send to a Friend
Benchmark analyst Bruce Jackson reiterated a Speculative Buy rating and $14.00 price target on Reviva Pharmaceuticals (NASDAQ: RVPH).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login